Assessment of time course of changes in antibody titers after vaccination with a Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Salk vaccine): DTap-wIPV to consider necessity of booster vaccinations.
Not Applicable
- Conditions
- Healthy children
- Registration Number
- JPRN-UMIN000016570
- Lead Sponsor
- The Japanese Society for Vaccinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Time course of changes in antibody titers Time course of changes in titers of antibodies to PT, pertussis FHA, diphtheria, tetanus, and highly-virulent polioviruses (types 1, 2, and 3) at the ages of 4-7years after DTaP-wIPV vaccination 2) Prevalence of diseases Pathological status of pertussis, diphtheria, tetanus, and VAPP until the time of blood collection
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of DTap-wIPV in eliciting immune responses in healthy children?
How does DTap-wIPV compare to other combination vaccines in terms of antibody persistence and booster necessity?
What biomarkers correlate with long-term antibody titer maintenance after DTap-wIPV vaccination?
What are the potential adverse events associated with DTap-wIPV in pediatric populations and their management?
Are there alternative inactivated poliovirus vaccine combinations with improved immunogenicity profiles for booster schedules?